OnKure Therapeutics (NASDAQ:OKUR – Get Free Report) was upgraded by research analysts at Lifesci Capital to a “strong-buy” rating in a research note issued on Thursday, Zacks.com reports.
Separately, Oppenheimer initiated coverage on OnKure Therapeutics in a research report on Thursday. They set an “outperform” rating and a $35.00 price objective on the stock.
Get Our Latest Stock Report on OnKure Therapeutics
OnKure Therapeutics Stock Performance
OnKure Therapeutics Company Profile
Reneo Pharmaceuticals Incis a clinical stage pharmaceutical company. It is focused on the development and commercialization of therapies for patients with rare, genetic, mitochondrial diseases. Reneo Pharmaceuticals Incis based in SAN DIEGO.
Featured Articles
- Five stocks we like better than OnKure Therapeutics
- Comparing and Trading High PE Ratio Stocks
- 3 Micro-Caps Set for Major Moves: Balancing Risk and Opportunity
- 3 Ways To Invest In Coffee, Other Than Drinking It
- Autodesk Named a “Top Pick” by Morgan Stanley—Is It Time to Buy?
- What is Insider Trading? What You Can Learn from Insider Trading
- 4 Quirky ETFs With Big Potential for Impressive Gains
Receive News & Ratings for OnKure Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OnKure Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
